12
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6321 |
Tofacitinib
托法替尼,Tasocitinib,CP-690550 |
ROCK; Apoptosis; JAK; Src | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Tofacitinib (Tasocitinib) 是口服小分子 Janus 激酶抑制剂,用于治疗中度至重度类风湿性关节炎。 | |||
T2398 |
Tofacitinib Citrate
CP-690550 citrate,柠檬酸托法替尼,枸橼酸托法替尼,Tasocitinib citrate,Tofacitinib (CP-690550) Citrate |
Apoptosis; Influenza Virus; JAK; Antibacterial; Antifungal | Angiogenesis; Apoptosis; Chromatin/Epigenetic; JAK/STAT signaling; Microbiology/Virology; Stem Cells |
Tofacitinib Citrate (CP-690550 citrate) 是 JAK1/2/3抑制剂,IC50分别为112,20 和 1 nM。它具有抗菌,抗真菌和抗病毒活性。 | |||
T70168 |
Tofacitinib HCl
|
Others | Others |
Tofacitinib HCl, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib HCl modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib HCl inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. | |||
T37638 |
Tofacitinib metabolite-1
|
Others | Others |
Tofacitinib metabolite-1, a derivative of Tofacitinib, which is a JAK inhibitor, is employed in studies focused on the pharmacokinetics and metabolism of tofacitinib[1][2]. | |||
T13426 |
(3R,4S)-Tofacitinib
|
Others | Others |
(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM). | |||
T13426L |
(3S,4S)-Tofacitinib
(3S,4S)-托法替尼 |
Others | Others |
(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor. | |||
T69958 |
Tofacitinib maleate
|
Others | Others |
Tofacitinib maleate, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib maleate modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib maleate inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. | |||
T13427 |
(3S,4R)-Tofacitinib
|
Others | Others |
(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM). | |||
T72406 |
Tofacitinib Prodrug-1
|
Others | Others |
Tofacitinib Prodrug-1 是减轻托法替尼 (Tofacitinib) 全身性不良反应的口服有效前药。Tofacitinib Prodrug-1 能在小鼠模型有效减轻恶唑酮诱导的结肠炎,具有低毒性,是治疗溃疡性结肠炎的潜在候选药物。 | |||
T31074 |
CP-690550A
Tofacitinib metabolite M2,CP-690,550A,UNII-Q7ZOK859UK |
Others | Others |
Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases. | |||
T69957 |
Quoromycin
|
Others | Others |
Quoromycin is a novel antivirulence agent against Vibrio vulnificus, inhibiting the quorum-sensing signaling pathway by controlling the DNA-binding affinity of SmcR and thus effectively alleviating the virulence of V. vulnificus in vitro and in vivo. | |||
T70167 |
BP-5-087
|
Others | Others |
BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TMIJ-0137 |
Tofacitinib-d3 Citrate
|
||
Tofacitinib-d3 Citrate 是 Tofacitinib Citrate 的氘代化合物。Tofacitinib Citrate 的 CAS 号为 540737-29-9。Tofacitinib citrate是JAK1/2/3抑制剂,IC50分别为112,20 和 1 nM。它具有抗菌,抗真菌和抗病毒活性。 |